Equip’s Transition

Equip Health recently sent medical and mental health treatment providers this referral solicitation email.

Notice the subject line which should be read exactly as written:

Subject: “Transition your highest-acuity ED patients—into acute, virtual care.”

That sentence is not casual marketing. It is the claim. It is also worthy of regulatory agency investigation.

Before the reader reaches the body of the email, Equip has combined three clinically loaded concepts: highest acuity, acute care, and virtual treatment. The result is not an access message. It is not a modest statement that medically stable patients may receive step down support at home. It is a solicitation asking providers to move the sickest eating disorder patients into a virtual program described as acute care.

Equip may attempt to walk back its representation and offer a narrower interpretation. It may say the representation meant patients who had already achieved medical stability and were appropriate for step down treatment. But that defense relies upon words the email did not use.

Equip did not limit the claim to patients who had been medically stabilized, medically cleared, or found no longer to need inpatient or residential care. It did not confine the solicitation to medically stable patients appropriate for step down treatment. The words it chose were broader, more aggressive, and more clinically consequential.

“Transition your highest-acuity ED patients into acute, virtual care.”

That is a placement claim.

In eating disorder treatment, highest acuity is not a branding term. It points toward patients with serious medical, psychiatric, nutritional, behavioral, or environmental risk. Depending on the case, the phrase may involve bradycardia, hypotension, syncope, electrolyte disturbance, severe malnutrition, refeeding risk, acute suicidality, self-harm, uncontrolled purging, compulsive exercise, laxative misuse, food refusal, failed lower levels of care, or a home setting unable to contain the illness.

Those are not convenience care problems. They are level of care problems.

Some require medical hospitalization. Others require psychiatric inpatient treatment. Some belong in residential care. Others may need PHP, IOP, or carefully monitored outpatient treatment after stabilization. The clinical issue is not whether virtual care can ever help. It plainly can. The issue is whether a fully virtual program should be marketed to referral sources as “acute” care for the “highest acuity” eating disorder patients.

Equip’s email says yes. The evidence does not justify that confidence.

The body of the email makes the subject line harder to dismiss. Equip tells providers that it is a “common misconception” that virtual eating disorder care is only for less complex patients seeking IOP or outpatient treatment. It says patients who are medically, psychologically, or socially complex, or recently hospitalized, can receive the structured support they need through Equip. It describes the company’s 100 percent virtual model as a direct alternative to residential treatment, PHP, and IOP. It claims more than 6,000 high acuity patients successfully treated in two years. It invokes medical safety, strict protocols, and the gold standard of family-based treatment.

Each phrase is material. Together, they create a net impression: Equip is not merely offering virtual outpatient care. It is positioning its model as a substitute for higher levels of care, including for patients described as high acuity or even highest acuity.

That is where the substantiation problem escalates.

FBT has evidence. Virtual FBT has a smaller and less mature evidence base. Equip’s proprietary virtual model is a separate proposition. A fully virtual model marketed as a direct alternative to residential treatment, PHP, and IOP is another proposition still.

In an attempt to gain legitimacy, Equip’s email collapses those categories.

Evidence for in person FBT cannot simply be transferred to virtual FBT. Evidence that virtual FBT may be feasible for selected medically stable patients cannot be stretched into proof that a virtual commercial platform is equivalent to higher levels of care. Company associated outcomes do not become independent validation because the model is built around a recognized therapy.

That is evidentiary laundering. A valid treatment principle is being used to support a broader commercial claim the public evidence has not established.

The existing virtual FBT literature appears to support a narrower statement: virtual FBT may be feasible, acceptable, and useful for selected patients, particularly medically stable adolescents and young adults with adequate family support and access to medical monitoring. That is meaningful. But it is not a finding of equivalence to in person FBT. It is not proof of non-inferiority. It is not evidence that residential care, PHP, or IOP can be replaced for patients who meet those levels of care.

No independent, third party, comparative trial has established that virtual FBT is as effective as in person FBT for adolescent anorexia nervosa. No independent objective trial appears to establish that Equip’s model is equivalent to standard in person FBT. No public independent evidence appears to show that Equip’s fully virtual program is clinically equivalent to residential treatment for patients who meet residential criteria.

Yet the email calls the model a direct alternative.

A direct alternative requires direct proof.

Residential treatment, PHP, and IOP are not interchangeable marketing categories. Each level exists because certain patients need more structure than ordinary outpatient care. At the upper end, care may require direct observation, medical stabilization, supervised meals, behavioral containment, psychiatric safety planning, or twenty-four-hour structure. Whether every program performs those functions well is a separate issue. The level of care exists because the functions are clinically necessary for some patients.

Equip’s model may provide real services: therapy, nutrition support, family coaching, medical coordination, remote meal support, protocols, and escalation. Those services can matter. They do not, by themselves, constitute acute care. They do not establish equivalence to residential treatment. They do not prove safe management of the highest acuity patients.

The distinction is not semantic. It is the patient safety line.

Equip’s own public materials reportedly recognize a limiting principle: the company describes its care as appropriate for medically stable patients and indicates that patients are medically cleared before enrollment. That qualifier is decisive. Medically stable step-down care is one proposition. Highest acuity acute virtual care is another.

The email blurs the difference.

“Medically complex” does not mean medically stable. “Recently hospitalized” does not mean ready for virtual care. “Would otherwise require residential treatment” does not mean safe to manage at home. “High acuity” is not an outcome. “Successfully treated” is not evidence unless the terms are defined and the failures are disclosed.

The claim that Equip has treated more than 6,000 high acuity patients in two years demands answers. What counted as high acuity? How was success defined? How many patients were screened but rejected? How many were excluded because they were medically unstable? How many lacked adequate caregiver support? How many dropped out? How many required hospitalizations during treatment? How many stepped up to residential, PHP, IOP, medical inpatient, or psychiatric inpatient care? How many relapsed after discharge? How many were lost to follow up? How many actually met independent residential criteria at the time of referral?

Without that denominator, “6,000 high acuity patients successfully treated” is a marketing plan, not scientific proof.

The phrase “grounded in medical safety” has the same defect. In a virtual model, medical safety depends on selection, exclusion, honest reporting, reliable caregivers, local medical access, timely vitals, timely labs, ECGs when indicated, and rapid escalation. Those dependencies may support appropriate virtual treatment for selected patients. They do not transform a remote program into an acute care setting.

Equip’s email made objective health claims in a commercial referral solicitation. The claims concerned acuity, medical safety, treatment success, and level of care substitution. They were directed to providers who influence where vulnerable patients receive care. If Equip cannot substantiate those claims with competent and reliable evidence specific to the representations made, the email is not aggressive education. It is deceptive health marketing. The same type of marketing the FTC has investigated with other providers in the past.

Commercial context reinforces the need for scrutiny. Equip is a venture backed virtual treatment company operating in a payer sensitive field where facility-based care is expensive and often contested. A virtual alternative to residential treatment is attractive to insurers. It is scalable. It may be cheaper to authorize. It can be framed as modern, accessible, and evidence based. None of that proves misconduct. It explains why broad claims about “highest acuity” and “acute virtual care” require exacting proof.

The public interest is greater because Equip is not operating only in the commercial insurance market. Equip states that more than seven million Medicaid members can access its services, that it accepts Medicaid plans in several states, and that it is working to expand across state Medicaid programs and managed care organizations. If a company markets a fully virtual model as acute care for high acuity eating disorder patients, or as a direct alternative to residential treatment, PHP, and IOP, the question is not limited to whether private families were persuaded by aggressive marketing. The question is whether Medicaid beneficiaries, Medicaid managed care plans, state Medicaid agencies, and public healthcare dollars may be relying on the same claims.

Medicaid participation requires a higher level of public scrutiny. Medicaid patients often have fewer covered alternatives, less access to specialized in person eating disorder treatment, and less practical ability to obtain independent review when a covered virtual option is presented as appropriate. If Equip means medically stable patients who have been screened and cleared for virtual treatment, it should say that with precision. If it means Medicaid patients who would otherwise meet criteria for residential, PHP, IOP, medical hospitalization, or psychiatric hospitalization, it should publish evidence strong enough to support that substitution.

Equip may criticize residential treatment. The residential sector has earned scrutiny. But the flaws of one system do not validate a commercial replacement. A company cannot attack higher levels of care as insufficiently proven, then market its own virtual model as a direct alternative without independent evidence commensurate with that claim.

The burden is simple.

If Equip means medically stable patients appropriate for step down care, it should say that. If Equip means highest acuity patients, it should produce the evidence. If Equip means a direct alternative to residential treatment, PHP, and IOP, it should publish the comparative data.

Produce the independent study showing virtual FBT is noninferior to in person FBT. Produce the independent study showing Equip’s proprietary model is equivalent to in person FBT. Produce the independent study showing a fully virtual model is a safe and effective direct alternative to residential treatment for patients who meet residential criteria. Publish the denominator. Publish exclusion criteria. Publish hospitalization rates. Publish step up rates. Publish dropout rates. Publish adverse events. Publish relapse data. Publish outcomes by diagnosis, acuity, medical risk, purging behavior, suicidality, weight status, prior hospitalization, and caregiver availability.

Until then, the email should be read for what it is: a commercial solicitation asking providers to transition the sickest eating disorder patients into a virtual model on claims Equip has not publicly proved.

Not proof.

Not science.

Not validated acute care.

Merely a sales document. And a sales document worthy of federal agency investigation at that.

Five Million Dollars is not a Victory. It is an Indictment.

The EDCoalition and some advocates are celebrating the June 12, 2026, announcement of the House Appropriations Committee’s advancement of $5 million for eating disorder prevention, screening, training, early detection, and related work. They posted, “We did it EDCoalition!”

In the narrow world of appropriations politics, some may call that a win. They believe that any federal recognition of eating disorders is better than silence. Others more appropriately call it, “dereliction of duty.”

But that is just one of the many problems. The baseline has been set so low that symbolic movement can be mistaken for serious action.

Five million dollars is not a serious federal commitment to eating disorder research. It is not close. Measured against the federal budget, comparable psychiatric and substance use conditions, the mortality rate of eating disorders, and twenty-five years of organized federal advocacy, the number is not a breakthrough. It is damning evidence of gross incompetence.

For 2026, the Congressional Budget Office projects total federal outlays at approximately $7.4 trillion. Against that number, $5 million for eating disorders represents about 0.0000676% of federal spending.

For greater perspective, for every $1 million the federal government spends, this eating disorder package represents roughly 68 cents.

That is not a national research priority. It is a rounding error with a press release.

A household comparison makes the number harder to hide. If an eating disorder professional earns $75,000 per year, the same percentage of her income donated toward eating disorder research would be … five cents.

One nickel.

That is the scale of “the victory” being celebrated.

Nor is the $5 million, in any meaningful scientific sense, $5 million for eating disorder research. Four million dollars is directed to the National Center of Excellence for Eating Disorders. The committee language describes provider engagement, pediatrician consultation, screening and treatment guidance, pediatric training models, prevention, early intervention, treatment protocols, education, training, and awareness. Those functions may be useful. They may improve identification. But they are not longitudinal mortality studies. They are not randomized clinical trials. They are not biological, genetic, neuropsychiatric, pharmacologic, or comparative treatment research at the scale the illness demands.

The remaining $1 million is labeled “Eating Disorders Research” under the HHS Office on Women’s Health. That line is narrow by design. Eating disorders affect women and girls, but they also affect men, boys, athletes, veterans, older adults, and people across race, income, and geography. A serious national research agenda would not be confined to one office, one demographic frame, or one million dollars.

If research means actual NIH scale investigation into causes, mortality, treatment outcomes, relapse, biological mechanisms, clinical standards, access, comparative efficacy, and prevention, then this package does not appear to do that.

Zero dollars in this package are appropriated to the NIH eating disorder research portfolio.

Zero dollars are described as new NIH grants for disease mechanism, clinical trials, longitudinal outcomes, mortality reduction, pharmacologic innovation, or treatment accountability.

Zero Dollars.

That is the headline.

The number becomes worse when placed against eating disorder mortality. ANAD reports that 10,200 deaths each year are the direct result of an eating disorder, roughly one death every 52 minutes. If the entire $5 million package is credited as eating disorder funding, it equals about $490 for each eating disorder death.

That is not valuation. It is scale. It is an insult to those who have died from eating disorders.

If only the $1 million line labeled “Eating Disorders Research” is counted, the figure falls to about $98 per death. If only new NIH research money specifically created by this package is counted, the figure is zero.

That is the damning arithmetic behind the celebration. But there is more.

Eating disorders are not obscure. They affect an estimated 28.8 million Americans over a lifetime. They carry serious medical risk. They intersect with anxiety, depression, trauma, substance use, suicide, cardiac complications, endocrine disruption, gastrointestinal injury, bone loss, infertility, malnutrition, and organ failure. They are not lifestyle problems. They are not boutique illnesses. They are not adolescent vanity disorders. They are lethal psychiatric and medical diseases.

Yet the federal response remains as if eating disorders did not exist at all.

Research disparity among other mental health issues is shocking. NIH estimated eating disorder research support at roughly $55 million in fiscal year 2024. Anxiety disorders received about $266 million. Depression received about $673 million. Schizophrenia received about $239 million. Drug abuse, through NIDA alone, received about $1.663 billion. Substance misuse received about $2.588 billion.

Those conditions deserve serious funding. The comparison does not prove they are overfunded. It proves something else: when the federal government treats a psychiatric or behavioral health condition as a research priority, it knows how to fund at scale.

Eating disorders are not treated that way.

The same point appears in federal spending outside health research. The federal government has been willing to identify, authorize, defend, or fund foreign and international programs in amounts that exceed or dwarf the entire eating disorder package. Publicly cited examples include:

$6 million for cultural tourism and local economic development in Egypt.

$20 million for Ahlan Simsim Iraq, a USAID funded Sesame Workshop affiliated program aimed at children in Iraq.

$24.6 million to build climate resilience in Honduras.

$13.4 million for civic engagement in Zimbabwe.

And nearly $11 million for armored personnel carriers for Uruguay’s quick reaction force. It staggers the imagination to know our federal government is spending more than twice as much on armored personnel carriers for Uruguay’s quick reaction force instead of eating disorder research.

On questionable domestic programs, the federal government has been willing to provide funding in amounts that equal the entire eating disorder package. Publicly cited examples include:

$5 million appropriated for potato breeding facilities in Idaho.

$5 million for historical publications and records grants.

$5 million for Native tourism activities.

$5 million for a harmful algal bloom demonstration program.

$5 million for algal carbon utilization to support data centers.

$5 million for a golden mussel watercraft inspection program in California.

$5 million for moving a local airport passenger terminal in Texas.

$5 million for a veterinary teaching clinic in Kentucky.

Those projects have their lobbyists, their local sponsors, and their bureaucratic justifications. Compared with the federal neglect of eating disorders, they are worthless priorities. They do not carry the mortality burden. They do not explain 10,200 deaths a year. They do not represent a national psychiatric and medical crisis. They do not leave families burying children after years of failed treatment, denied care, and inadequate science.

The comparison is not unfair. It is the point. Five million dollars is a routine federal line item for potatoes, mussels, algae, airports, tourism, records, and veterinary facilities. For eating disorders, it is being sold as a national victory. It is actually a national disgrace.

Washington can move tens of millions of dollars when a priority is visible. It can defend large sums when a program has institutional force behind it. It can spend at scale when the issue is treated as urgent. Eating disorders, despite the mortality burden, remain funded as if the deaths are regrettable but politically inexpensive.

Which brings the focus back to the Eating Disorders Coalition.

The EDCoalition has existed since 2000. After more than a quarter century of organized federal advocacy, the question is not why Congress did so little. The question is why the leading federal eating disorder advocacy organization is celebrating so little and accomplishing even less. Who is funding the EDCoalition for this gross incompetence? For that matter, let’s explore that gross incompetence.

Let us start with the size of the ask. A movement serious about research would not treat a few million dollars as a historic achievement. It would be demanding a major NIH eating disorder initiative, a national mortality study, longitudinal outcomes data, comparative treatment research, relapse studies, treatment safety research, and real accountability for levels of care. It would insist that eating disorders be funded in proportion to their lethality, prevalence, and medical complexity.

Instead, we are left to wonder who is funding the EDCoalition and diverting attention away from those important issues? Who is funding this betrayal of public trust and setting the agenda? Answers to which will never be supplied. Transparency is optional.

Instead, we watch with incredulity EDCoalition celebrating a meaningless $5 million appropriation, most of it directed toward screening, training, education, consultation, early detection, and technical assistance.

Those are support functions. They are not a research agenda.

In some ways, no appropriation at all would have been more honest. Zero dollars would have plainly exposed the neglect. It could have become a legitimate rallying point. Families, clinicians, researchers, and patients could have pointed to the absence and said: this is what abandonment looks like. Why does this exist?

Five million dollars does something more dangerous. It creates the appearance of progress while preserving the reality of neglect. It gives Congress a talking point. It gives advocacy organizations a fundraising headline. It lets the field announce movement without forcing the community to confront how little was actually done.

That is why the celebration is not harmless.

A token appropriation can anesthetize outrage. It allows policymakers to praise families, clinicians, researchers, and people with lived experience while allocating sums that would not sustain a serious national research agenda for one lethal disease. It allows the public to hear that eating disorders received funding without understanding that the funding is microscopic. It allows an advocacy organization founded twenty-five years ago to announce a win instead of admitting that the federal response remains grossly inadequate.

The failure is not that nothing happened.

The failure is that so little happened, and the public was asked to applaud.

If eating disorders are serious, life-threatening illnesses, fund them that way. If early detection saves lives, fund the research that proves what works. If evidence-based treatment matters, fund comparative outcomes, relapse data, mortality studies, program accountability, and treatment safety. If one person dies every 52 minutes, stop pretending $490 per death is a victory.

Five million dollars is not progress at scale. It is not a research commitment. It is not a national response. It is a measure of how little the crisis still matters in federal policy. And apparently, with the lack of public outrage, with the failure to demand answers and accountability, the eating disorder community simply does not care either.

That is the indictment.

The eating disorder field has spent decades asking families to trust it. Trust the treatment center. Trust the intake coordinator. Trust the website. Trust the words “evidence based.” Trust the branded clinical model. Trust the promise that the program knows what it is doing because the patient is too sick, the parents are too frightened, and the stakes are too immediate for careful comparative shopping.

But trust is not a standard of care. And neither are marketing, credentials, nor an impactful website. In a medical and psychiatric illness with substantial mortality risk, high relapse rates, serious medical complications, and profound psychiatric comorbidity, the absence of enforceable, generally accepted standards of care is not a theoretical defect. It is an operating condition that places patients in danger.

The eating disorder community has long understood the problem, even when it has not solved it. In 2008, the Academy for Eating Disorders Credentialing Task Force produced draft recommendations for residential and inpatient eating disorder program accreditation. Some of the most respected, knowledgeable professionals participated in this collaboration.

The document did not read like an aspirational brochure. It read like a blueprint for patient protection. It called for standards in assessment and treatment planning, treatment delivery, quality improvement, specialized protocols, outcome measurement, and accreditation. Its stated purposes were to safeguard patients and families seeking inpatient and residential care, improve the quality of care offered by programs, and provide a benchmark for third party payers. That language is important. It shows that the field knew, at least by then, that eating disorder treatment required more than general mental health licensure and more than ordinary institutional accreditation.

The AED standards also identified the core duties that any serious eating disorder program should recognize. Screening and intake should assess medical stability, psychiatric status, nutritional status, substance use, special needs, and developmental appropriateness. Admission should be a comprehensive interdisciplinary process involving medical, psychiatric, psychological, nutritional, and biopsychosocial assessment. Treatment planning should be timely, documented, individualized, and regularly reviewed. Continuity of care should include prompt communication with appropriate providers. Discharge planning should begin at admission and include specific follow up care. Treatment delivery should include psychological, medical, nutritional, and psychiatric care. Programs should accurately describe their licensure, staffing, levels of medical care, treatment team composition, emergency protocols, costs, insurance participation, treatment duration, discharge criteria, staff qualifications, and continuing education. Outcomes should be measured, not guessed. Quality improvement should be ongoing, documented, and tied to actual patient results.

The field knew what a safety framework looked like. It knew patients needed medical screening, physician access, psychiatric care, nutrition expertise, discharge planning, family involvement, trained staff, outcome measurement, and transparent program information. It knew residential and inpatient programs were not ordinary therapy offices with beds. They were controlled treatment environments for patients with complex medical and psychiatric illnesses. Yet these standards were abandoned. They were never adopted nor enforced. And that is the indictment.

Building up to 2008.

This was before the Mental Health Parity Act of 2008 was passed into law. It was before the Affordable Care Act was enacted. It was before the scourge of COVID. It was also largely before the private equity gold rush into the eating disorder industry began.

When a field lacks generally accepted standards of care, it does not become more flexible. It becomes less accountable. Every treatment center can claim excellence. Every program can call itself evidence based. Every operator can define “appropriate care” around its own staffing model, payer contracts, census pressures, and clinical philosophy. A family trying to decide where to send a medically fragile child or adult is left to compare slogans. A physician trying to refer a patient is forced to rely on reputation, relationships, and sales materials. An insurer can exploit ambiguity by denying care as unnecessary. A treatment center can exploit ambiguity by selling care as indispensable. The patient is then caught between two industries, each invoking medical necessity when it serves its financial interest.

The phrase “evidence-based treatment” illustrates the collapse. In any responsible medical field, evidence-based care should mean that a treatment is supported by research, delivered with fidelity, matched to diagnosis and level of care, monitored for safety, and evaluated by outcomes. In eating disorder treatment, the phrase has too often become a branding device. It may refer to CBT, DBT, FBT, exposure work, nutrition rehabilitation, medical monitoring, group therapy, experiential therapy, or a proprietary blend of whatever the program happens to offer.

Without a standard which requires programs to identify which treatment is being used, why it is appropriate, who is trained to deliver it, how fidelity is monitored, and what outcomes are achieved, “evidence based” becomes a label detached from evidence.

The harm is not semantic. Eating disorders kill. They injure. They produce cardiac instability, electrolyte abnormalities, endocrine disruption, bone loss, gastrointestinal complications, renal stress, refeeding risk, suicidality, and profound psychiatric comorbidity. They also deceive systems that rely on visible severity. A patient can appear medically stable until the lab work, EKG, weight trajectory, purging history, exercise behavior, or refeeding risk says otherwise. A patient can be in a larger body and still be medically unstable. A patient can be “normal weight” and dying. A patient can be discharged because insurance will not pay, retained because a bed must be filled, stepped down because the program has no capacity, or admitted because the program has capacity even when a different level of care would be safer.

The absence of standards increases mortality risk because it removes the guardrails that prevent predictable harm. Certainly, the lack of standards does not cause every death. It does not explain every bad outcome. But it allows dangerous variation in medical screening, level of care decisions, staff training, treatment planning, discharge readiness, and continuity of care. In a lethal illness, dangerous variation is not a neutral administrative problem. It is a patient safety failure.

The mortality problem is compounded by misunderstanding. Culturally, eating disorders are still often reduced to vanity, dieting, thinness, control, adolescence, or female distress. That public misunderstanding persists partly because the professional system has not spoken with one disciplined voice. If the field itself cannot agree on what competent care requires, it cannot expect legislators, medical schools, insurers, journalists, families, or courts to understand the illness with precision. Fragmentation creates confusion. Confusion creates delay. Delay creates medical deterioration. In the space between first symptoms and competent intervention, patients become sicker.

The legal system has already exposed the danger of this absence. In the behavioral health coverage battles surrounding generally accepted standards of care, eating disorders should have been central. Yet when courts and insurers search for recognized standards, eating disorder specific standards have often appeared fragmented, inconsistent, or conspicuously absent from the sources treated as authoritative. That absence sends a devastating message. The illness is deadly enough to require intensive treatment, expensive enough to bankrupt families, complex enough to require interdisciplinary care, but not organized enough to present one enforceable standard to the systems that control access and accountability.

Nor did private equity create this issue. It simply entered a disorderly field and found opportunity.

That distinction matters. The eating disorder field’s failure to establish enforceable standards predated much of the private equity consolidation. But once investment capital entered the residential and intensive treatment market, the absence of standards became commercially useful. A PE backed platform benefits from scalability. Scalability requires replicable operations, predictable margins, payer strategy, labor control, census management, and brand extension. In a field with enforceable clinical standards, those pressures collide with mandatory staffing, outcome reporting, medical coverage, training, supervision, discharge criteria, and transparent patient safety obligations. In a field without enforceable standards, those pressures can be converted into business judgment.

The AED standards make the private equity question sharper, not softer. By 2008, the field had articulated the need for eating disorder specific accreditation, prompt medical screening, interdisciplinary assessment, four core treatment components, nutritional rehabilitation goals, trained staff, continuing education, transparent financial information, discharge planning, quality improvement, and outcome measurement. Any serious investor entering or expanding in the eating disorder treatment market after that point had industry notice that residential and inpatient eating disorder care required specialized safeguards. The blueprint existed. The failure was not a lack of imagination. It was a lack of enforcement.

Measured against those standards, private equity’s role was not merely ownership. It was the commercialization of ambiguity. PE backed entities could acquire respected clinical brands, consolidate markets, add locations, advertise comprehensive care, pursue higher levels of reimbursement, and present themselves as national solutions without being forced to prove standardized outcomes across the platform. They could market compassion while operating under financial structures that reward growth, utilization, and eventual sale. They could describe themselves as evidence based without submitting to a universally accepted, independently audited eating disorder standard that measured whether the care advertised was the care delivered.

This is also why standards are important. Standards do not guarantee recovery. They do not eliminate clinical judgment. They do not reduce complex human beings to checklists. Properly designed, they do the opposite. They preserve clinical judgment by defining the minimum conditions under which judgment can be trusted. They require that a patient be medically assessed before placement. They require that a program be honest about its capabilities. They require that treatment be individualized, documented, and reviewed. They require that medical, psychiatric, psychological, and nutritional care all exist in fact, not only in marketing. They require that programs measure outcomes in a way that survives scrutiny. They make it harder for a center to sell a level of care it cannot safely provide. They make it harder for an insurer to deny a level of care the patient medically needs. They give families a way to distinguish treatment from theater.

The eating disorder community has paid a severe price for its failure to impose those minimum conditions. Families have been left to investigate facilities while in crisis. Patients have been moved through levels of care without clear, enforceable criteria. Clinicians have been forced to operate in a landscape where “specialist” can mean rigorous training or little more than self- selection. Payers have been able to exploit inconsistency. Treatment centers have been able to exploit fear. Private equity has been able to exploit both.

The result is a field that too often asks for deference without submitting to discipline. It asks insurers to pay for care while failing to create uniform proof of what competent care requires. It asks families to trust programs while permitting those programs to define their own excellence. It asks physicians to refer into higher levels of care while failing to ensure that those levels of care meet eating disorder specific standards. It asks the public to understand eating disorders as serious medical and psychiatric illnesses while tolerating a treatment marketplace that sometimes behaves as though seriousness can be inferred from price.

Purportedly, this topic has been discussed on numerous occasions by various organizations and individuals. On a few occasions, the topic has even gone past the discussion stage. In 2022, the American Psychiatric Association drafted new Practice Guidelines for the Treatment of Eating Disorders. On February 27, 2023, the APA announced it had adopted these guidelines. But there was a proviso. The press release also stated, “APA’s own “Proper Use of Guidelines” section says the guidelines are not a statement of the standard of care, do not mandate a particular course of medical care, do not substitute for clinician judgment, and are voluntary.”

In late 2025, the DSM Steering Committee proposed new eating disorder severity guidelines to be adopted and included in the DSM-V-TR or the next derivation of the DSM. Again, the warning language appears, The previously mentioned limitations apply equally to this proposal.

Effectively meaning … there has been some discussions. But, no effective, collaborative, broad-based action. Talk? Some. Solutions? None.

The solution is not another voluntary badge. It is not another proprietary credential. It is not another conference panel, white paper, or consensus statement that can be ignored by the next operator with a marketing budget. The solution is enforceable, eating disorder specific standards of care tied to accreditation, licensure, reimbursement, outcome reporting, and medical education. The standards must require medical risk assessment, refeeding competence, interdisciplinary treatment, trained staff, transparent levels of care, family involvement where appropriate, discharge planning, continuity of care, independent outcome measurement, and external accountability. They must apply to nonprofit programs, academic programs, independent centers, and PE backed platforms alike. They must be forward thinking taking into account the seismic changes which have occurred in the last five years impacting eating disorders.

The field does not need to start from scratch. The AED standards showed the beginning of the map. Later guidelines and center of excellence proposals added other pieces. The scientific literature has expanded. The public burden data have become harder to ignore. The litigation record has grown. Families have told the truth at great cost. The missing ingredient is not knowledge. It is institutional will.

An eating disorder treatment system without generally accepted standards of care is not a system. It is a marketplace. In that marketplace, the sickest patients are the least able to judge quality, the most desperate families are the easiest to persuade, the most expensive care is not always the most effective, and the most polished brands are not always the safest. That is not medicine. That is exposure.

The eating disorder community must decide whether it exists to protect patients or to protect the institutions that claim to serve them. If it chooses patients, it must accept enforceable standards, transparent outcomes, real accountability, and scrutiny of financial structures that place growth over care. If it refuses, then the verdict writes itself: the system knew the danger, possessed the tools to reduce it, and chose fragmentation over protection.

A patient refuses breakfast. A parent tries to supervise lunch between work calls. By dinner, food has been hidden, exercise has been concealed, and the number on the home scale depends on whether anyone was watching closely enough. The care team appears by video. The eating disorder remains in the house.

That is the promise and the risk of virtual eating disorder care. Recovery can happen at home only when the home can safely become part of the treatment system.

Equip Health did not enter the eating disorder field quietly. It loudly arrived with a prosecution of the existing system. In Equip’s telling, residential treatment was expensive, disruptive, inaccessible, opaque, and insufficiently evidence based. Families were being asked to send children away. Patients were cycling in and out of facilities. According to Equip’s public rhetoric, families were spending large sums of money on care that did not reliably produce recovery.

That critique landed because much of it contained truth. But shadows and shades of truth also exist in the critique.

First, there is no generally accepted standards of care for eating disorders. A basic, crucial priority. The medical and mental health fields have known about eating disorders for literally decades. And yet, the eating disorder field cannot collaborate and come up with generally accepted standards of care. That, in and of itself, is a felony-like indictment against the system and everyone in it.

Eating disorder treatment in the United States is fragmented, expensive, unevenly regulated, and often inaccessible. Many families cannot find trained clinicians. Many insurers deny care until a patient is medically worse. Some residential programs have overpromised, underdelivered, or sold safety without providing it.

But Equip’s argument deserves the same scrutiny Equip applies to residential treatment. Once a company attacks an entire level of care while selling its own substitute, the question is no longer whether the old system has flaws. The question is whether the replacement has proven what it claims.

On that question, the public record is much thinner than Equip’s marketing.

Equip’s model is simple to describe and difficult to validate. It sells virtual, home based eating disorder treatment built around family-based treatment, a multidisciplinary team, peer and family mentors, medical oversight, therapy, nutrition support, and payer reimbursement. It presents this model as evidence-based care delivered without uprooting a patient’s life. It also presents itself as an alternative to the traditional pathway that moves patients among inpatient, residential, partial hospitalization, intensive outpatient, and outpatient care.

And all delivered through the convenience of your laptop screen.

The problem is not that virtual care cannot help some patients. It plainly can. Family based treatment has strong support for adolescents with restrictive eating disorders. Telehealth can expand access. Many families live nowhere near a qualified eating disorder clinician. A home-based model can preserve school, work, family contact, and ordinary life.

The problem is the leap from that defensible proposition to the broader commercial narrative: that a venture backed, payer aligned, virtual platform can stand as a scalable answer to treatment settings that provide supervision, containment, meal observation, and immediate intervention for medically and psychiatrically fragile patients.

Equip has been willing to put residential treatment on trial. Its own record should now be tried.

The Anti-Residential Pitch

Equip’s leadership has publicly criticized residential treatment with unusual directness. Kristina Saffran, Equip’s cofounder and chief executive, wrote that residential settings had become the go to treatment for adults and adolescents despite “no data” on effectiveness. She described watching people cycle in and out of those centers. Equip’s public materials contrast its virtual approach with sending a child away to a residential facility.

Those are not mild statements. They are market positioning. They tell families, clinicians, and payers that residential treatment is not merely costly or unpleasant, but suspect.

That positioning matters because Equip is not an academic critique. It is a company selling the alternative.

When a non-profit advocate says the residential industry needs reform, that is one thing. When a venture backed provider says residential care lacks evidence while asking insurers to pay for its own model, the statement has commercial force. It helps redirect demand. It helps shape payer behavior. It helps define what families are told counts as serious care.

Equip is entitled to criticize residential treatment. But criticism is not proof. A company cannot use the weakness of one sector as evidence that its own model has solved the problem.

The Evidence Gap

Equip’s strongest public evidence appears to be internal or affiliated research, payer reported outcomes, and observational data from patients treated inside its own system. That is not meaningless. It is also not the same as independent proof.

The public record does not show an independent randomized trial proving that Equip’s proprietary five-person virtual model is equivalent to residential treatment, partial hospitalization, or intensive outpatient care for high acuity eating disorder patients. It does not show long term independent relapse data sufficient to support sweeping claims about durable recovery. It does not show that virtual care can safely replace higher levels of care for patients who need supervision, structure, meal support, bathroom monitoring, medical stabilization, or emergency psychiatric containment.

Equip’s studies may show improvement among selected patients. But selection is the issue. Who was admitted? Who was excluded? Who dropped out? Who was hospitalized? Who stepped up to a higher level of care? Who deteriorated? Who was lost to follow up? Who had caregiver support strong enough to make the model work? Who did not?

A treatment model built around home supervision depends on the home. That is not a minor variable. It is the model.

Equip can say its approach is adapted from evidence-based, family-based treatment. However, that does not establish that every expansion of the model, every diagnosis treated, every acuity level accepted, every payer pathway created, and every substitution for facility-based care is equally proven. The public studies do not appear to answer the hardest question: not whether some patients improve with Equip, but whether patients who would otherwise need a higher level of care are safe and adequately treated when routed into a virtual platform.

That distinction is the center of the case against Equip’s public narrative.

The Home Becomes the Facility

Equip’s model does not merely treat patients at home. It turns the home into the treatment site.

That shift is profound. In residential care, staff are tasked to monitor meals, watch for purging, interrupt compensatory behavior, respond to refusal, observe medical deterioration, and provide containment. In Equip’s model, that burden moves into the household. Parents and caregivers become meal supervisors. Families become behavior monitors. Home scales become clinical instruments. Kitchens, bedrooms, bathrooms, grocery stores, and exercise routines become part of the treatment environment.

That can work in the right family. It can also fail for reasons that have nothing to do with motivation. Some parents work jobs that do not allow meal supervision. Some households are divided by divorce, conflict, poverty, addiction, violence, illness, or exhaustion. Some patients are adults whose families have no legal or practical control. Some caregivers are too frightened, too traumatized, too clinically naive, or too financially strained to perform the job the model assigns to them.

Recovery at home is a clinical model only when the home can safely become a clinic.

That is the part of the promise families need to hear clearly. Virtual treatment is not simply a more humane version of higher care. It is a transfer of clinical labor into the household. If Equip excludes patients whose homes cannot support that transfer, its model is narrower than its public rhetoric. If it accepts them anyway, the safety questions become more serious.

The Business Model Behind the Clinical Claim

Equip’s financial structure sharpens the concern. Public releases and reports identify F Prime Capital, Optum Ventures, .406 Ventures, The Chernin Group, Tiger Global, General Catalyst, Katie Couric Media, and Alex Morgan among Equip’s publicly named investors, with Kerry Washington later announced as an advisor and investor. Equip’s public and regulatory record also shows substantial later equity financing: a 2024 Form D amendment reported approximately $35 million sold to five investors, and a September 2025 Form D amendment reported approximately $54.1 million sold to twelve investors. Those later Form D filings do not publicly identify the investors.

That capital does not come without expectations. Venture backed health care companies are not built to remain small, cautious, and slow. They are built to scale. Scaling a virtual eating disorder provider means adding lives, adding states, adding payer contracts, expanding diagnoses, increasing referrals, standardizing protocols, and demonstrating that care can be delivered at lower cost than facility-based treatment.

Again, none of that is inherently improper. But it creates pressure. And in health care, pressure travels.

It travels into admission criteria. It travels into marketing claims and payer conversations. It travels into outcome metrics. It travels into decisions about which patients can be treated virtually and how long a company waits before recommending a higher level of care.

The Optum Ventures investment is especially important. Optum Ventures led Equip’s Series A offering. Optum is part of the UnitedHealth Group ecosystem, one of the most powerful payer and health services structures in American medicine. Equip also publicly identifies UnitedHealthcare and Optum among insurance plans connected to coverage. A payer connected investor in a virtual model that can reduce use of residential or partial hospitalization care is not proof of misconduct. It is, however, a bright red discovery target.

The question is direct: Was Equip marketed to payers as a clinically superior model, a lower cost substitute, or both?

Aetna’s public discussion of its value-based arrangement with Equip adds weight to that question. Aetna described the collaboration as a way to standardize outcomes, reduce disruption, and control costs. It reported patient progress and symptom reductions among Aetna members treated by Equip. It also framed the arrangement as a value-based success.

That may be good payer management. It may also be the precise place where clinical judgment and cost containment begin to blur.

The broader question is not limited to Optum or Aetna. Who benefits when higher levels of care are avoided? Payers benefit from fewer residential, PHP, and IOP claims. Virtual providers benefit from payer referrals. Investors benefit from scalable treatment with lower facility costs. Families may benefit when virtual care is clinically appropriate. But patients may be harmed when a lower cost model substitutes for needed containment.

If a patient is routed to Equip because virtual care is clinically appropriate, that is one thing. But, if a patient is routed to Equip because residential or partial hospitalization is expensive, difficult to authorize, or disfavored by the payer, that is another. The public record does not answer that question. It demands that the question be asked.

What Virtual Care Cannot Do

Equip’s model rests on an appealing premise: recovery should happen in real life. But eating disorders often thrive in real life. They hide in bathrooms, bedrooms, kitchens, grocery stores, exercise routines, laptops, family conflict, secrecy, shame, manipulation, and medical instability. The disorder is not merely a thought pattern that can be discussed over video. It is behavior, physiology, risk, concealment, and control.

Virtual care cannot sit at the table for every meal. It cannot watch a patient after dinner. It cannot prevent purging in the bathroom. It cannot stop compulsive exercise in the bedroom at midnight. It cannot verify every weight. It cannot take vital signs unless someone reliable takes them. It cannot create a safe household where one does not exist. It cannot supply twenty-four-hour containment when a patient is suicidal, medically unstable, actively restricting, purging, fainting, manipulating weight, or refusing food.

Medical instability is not a branding problem. It can mean bradycardia, orthostatic instability, electrolyte disturbance, dehydration, syncope, refeeding risk, laxative abuse, acute self-harm, or suicidality. Those risks do not become manageable because treatment is convenient. They require accurate detection, rapid escalation, and honest limits.

Equip can respond that those patients require hospital stabilization or a different level of care. That answer is clinically necessary. It also narrows the model. It means Equip’s public promise depends on careful exclusion, rapid escalation, and honest recognition of what virtual care cannot safely manage.

That is where the public rhetoric becomes dangerous. The broader the attack on residential care, the easier it becomes for families and payers to hear that higher care is outdated, excessive, or unnecessary. The broader the claim that recovery can happen at home, the easier it becomes to underestimate the patients for whom home is not a treatment setting. It is the site of the illness.

The Missing Denominator

Equip and its payer partners have reported favorable outcomes. But every outcome claim in behavioral health lives or dies by its denominator.

How many patients entered treatment? How many completed it? How many left early? How many required hospitalizations? How many stepped up to residential, PHP, or IOP? How many had emergency interventions? How many relapsed six months later? How many were excluded before admission because they were too medically unstable, too psychiatrically acute, too unsupported at home, or too difficult to monitor? How many families could not perform the work the model requires?

Without that denominator, success rates risk becoming marketing assets rather than scientific findings.

This is especially important because Equip has criticized residential treatment for cycling patients through care. If Equip wants to make relapse, readmission, and revolving door treatment part of the indictment against residential providers, then Equip must disclose comparable data for its own model. Not just symptom improvement among engaged patients. Not just progress among payer members. Not just weight restoration among those who remained in care. The complete denominator.

The public record does not yet supply that level of independent validation.

What Would Prove Equip Right

Equip could answer much of this criticism with evidence. Not slogans. Not affiliated outcome summaries. Not payer success stories. Evidence.

Independent randomized or well-matched comparative studies would matter. Full denominator reporting would matter. As would comparable acuity groups. Long term relapse and readmission data are material. Adverse event reporting and transparent hospitalization and step up rates matter. Independent replication by researchers without financial ties to Equip are imperative. Payer savings data separated from clinical outcomes. Clear criteria for patients who met residential level of care but were treated virtually must be disclosed.

That is what proof looks like.

Until then, Equip has not disproven residential treatment. It has built a business arguing that many patients should not need it.

The Real Indictment

Equip’s vulnerability is not that virtual care never works. That would be false and unserious. The vulnerability is that Equip has built a business around a claim that needs far more independent proof than the public record appears to provide.

Equip has criticized private equity owned residential treatment while raising venture capital. It has presented home based virtual care as evidence based and scalable. It has partnered with insurers in arrangements that explicitly include cost control. It has accepted investment from a payer connected venture fund. It has published or promoted favorable outcomes while the hardest questions about exclusion, dropout, escalation, relapse, adverse events, and long-term recovery remain unresolved in the public domain… and undisclosed.

The issue is not whether Equip is another false hope story to desperate families. The story is that Equip is a test case for a larger transformation in American behavioral health: the conversion of complex, high risk care into virtual, scalable, payer friendly products.

That transformation may improve access for some patients. It may also produce a cheaper treatment pathway that looks most successful when the sickest, least supported, hardest to monitor patients are filtered out, stepped up, or missing from the denominator.

The eating disorder field has already seen what happens when treatment is sold faster than it is proven. Families are desperate. Insurers are cost conscious. Investors want growth. Clinicians are scarce. Patients are vulnerable. In that environment, the company that claims to have solved access, cost, evidence, and continuity deserves heightened scrutiny precisely because the promise is so attractive.

Equip put private equity owned residential treatment on trial. Now, Equip should produce the evidence for its own case.

Publish the full denominator. Publish step up rates. Publish hospitalization rates. Publish adverse events. Publish dropout data. Publish relapse data. Publish payer savings data. Publish the criteria used when patients met residential level of care but were treated virtually. Publish the conflicts.

Then the field can judge whether Equip has built a breakthrough. Or merely a scalable workaround for expensive care.

The March 2026 jury verdict in Los Angeles against Meta and Google, paired with the preceding $375 million New Mexico verdict, marks a structural shift in how courts conceptualize harm arising from social media platforms. These cases do not merely expand liability; they reframe the legal ontology of digital platforms from neutral intermediaries into potentially defective consumer products.

For eating disorders, conditions already deeply entangled with algorithmic amplification, body image distortion, and compulsive engagement, this shift is especially consequential. The emerging litigation theory may provide, for the first time, a coherent legal pathway to attribute causation and duty in eating disorder related harm.

In the past, Section 230 of the Communications Decency Act (47 U.S.C. § 230) provided a strong defense for social media platforms. This section states in relevant part:

“No provider or user of an interactive computer service shall be treated as the publisher or speaker of any information provided by another information content provider.”

This is often described as broad immunity, but more precisely it is a liability shield against publisher-based claims, not a general immunity from all wrongdoing.

The way in which this defense operates is that a court applies a three-part test. A defendant (e.g., Meta, Google) is protected under §230 if:

It is a provider of an interactive computer service
The claim treats it as a publisher or speaker
The content at issue was provided by a third-party content provider

If all three are satisfied a claim is barred.

Section 230 was designed to encourage online platforms to host user content, avoid crushing liability for user-generated speech and promote moderation without penalizing platforms. In short, platforms are not liable for what users say.

Prior eating disorder related litigation typically failed because courts viewed the harm as derivative of third-party content. For example; users post “thinspiration” or extreme dieting content, Plaintiff is harmed by exposure, and; platform’s sole role was hosting or distributing that content. The conclusion? § 230 applied and the case was dismissed.

The recent Meta/Google verdicts succeed because plaintiffs changed the theory of liability. The old framing (fails under §230): “You allowed harmful content to exist.” Case dismissed.

The new framing (survives §230): “You designed a system that predictably causes harm.” This is the doctrinal pivot.

§ 230 did not protect Meta and Google in the recent cases because the plaintiffs targeted conduct not content. In these cases, plaintiffs argued the harm arose from addictive design features and algorithmic amplification mechanisms. The plaintiffs did not argue that damage arose from a specific post. Thus, the platform is being sued for its own conduct, not third-party speech.

Algorithmic Amplification as Independent Conduct

This is one of the most important legal developments. Historically, courts often treated recommendations as publishing. Now, plaintiffs argue that algorithms are behavioral engineering systems because they; analyze user psychology, optimize for engagement and escalate exposure to harmful material.

This reframes algorithms as active conduct, not passive publication.

Section 230 was never designed to address defective products. In the Los Angeles case, the theory was the platform itself is the product and its design was unreasonably dangerous. This avoids §230 dismissal because the claim does not depend on who created the content. Instead, it focused on how the system functions.

Defendants often argue “but for content” trap, i.e. without third party content, there is no harm so §230 applies and the case should be dismissed.

Plaintiffs successfully avoided this by arguing that the harm arose from compulsive engagement loops and reinforcement cycles. The content is merely input and NOT the legal basis of liability.

This distinction is subtle but decisive.

Also, the plaintiffs were able to bring forth evidence that the platforms knew about harm (e.g., to teens, body image, ED risk) but continued optimizing engagement anyway. This evidence supports claims of negligence, recklessness and malice. This strengthens the argument that the wrongdoing lies in corporate decision making, not user content.

Why This Matters Specifically for Eating Disorders

ED Harm Fits the “Design, Not Content” Model. Eating disorders are not typically triggered by a single post. But by repeated exposure, escalating comparison and behavioral reinforcement. These are clearly algorithmic phenomena.

Unlike traditional media, social media platforms can identify users engaging with dieting content and body comparison content. This increases the likelihood of exposure. This frames a plaintiff’s argument as harm is not incidental, it is systematically intensified. There is also substantial evidence that social comparison leads to body dissatisfaction and repeated exposure leads to disordered eating behaviors

This makes it easier to argue that harm was predictable, foreseeable and safer alternatives were available.

The War is not over

It is important to note that Section 230 is not “dead.” It is being narrowed at the margins. Meta and Google still have strong appellate arguments. They will plausibly argue that algorithms are protected editorial judgment. As such, Section 230 should apply.

They may argue algorithmic curation is protected speech and liability chills expression. They undoubtedly will attempt to re-characterize all harm as ultimately stemming from user content. If successful, §230 could be reinstated on appeal.

Section 230 failed in these cases not because courts rejected it outright, but because Plaintiffs successfully changed the question. Instead of asking, “Are platforms responsible for user content?” They asked, “Are platforms responsible for designing systems that cause harm?”

That shift moves the case outside §230’s core protection, aligns with product liability and negligence frameworks and is particularly powerful in contexts like eating disorders.

If this theory holds on appeal, it will open the door to large scale ED litigation. It could force platforms to redesign engagement systems and implement youth protections.

Increased Eating Disorder Liability

For ED-related claims, liability may no longer depend on identifying specific harmful posts. Instead, plaintiffs can target recommendation algorithms, engagement loops (likes, scroll, autoplay) and behavioral reinforcement systems. This aligns directly with how ED pathology operates: repetition, reinforcement, and escalation, not isolated exposure.

Historically, ED-related litigation struggled with causation; eating disorders are multifactorial (genetics, trauma, culture) and Courts viewed platform influence as too attenuated.

The recent verdicts suggest juries are now willing to accept alternatives. The Los Angeles case framed harm through addiction mechanics; compulsive use, reinforcement loops and diminished control. This maps closely onto ED pathology; compulsive restriction, bingeing, or purging, reinforcement through comparison and validation and escalating behavioral cycles.

Unlike traditional media, social media platforms learn user vulnerabilities and optimize content delivery accordingly. For ED claims, this enables arguments that platforms did not merely expose users to harmful content. They systematically increased exposure based on detected susceptibility.

This is a qualitatively different form of causation, not passive distribution, but active behavioral shaping.

Among potential harm categories, EDs are uniquely positioned for litigation success due to a high predictability of harm. There is extensive internal and external research linking social comparison → body dissatisfaction → disordered eating. We now know that social media platforms can track repeated viewing of weight loss content, thinspiration and calorie restriction narratives. This creates a potential evidentiary record of foreseeable harm combined with continued amplification.

Courts are especially receptive to harms affecting minors and failure to implement protective measures. ED onset often occurs during adolescence, aligning directly with peak social media usage and peak psychological vulnerability.

Long-Term Structural Changes

As a result of these cases, we may see an emergence of “Digital Duty of Care” particularly for minors. Social media platforms may be held to standards similar to product safety law and pharmaceutical risk disclosure. Courts may formalize liability tied to predictive amplification of harm. And we may see potential legislation impacting youth specific design standards, limits on engagement optimization and/or mandatory transparency for algorithmic systems.

We may also see evolving clinical implications for eating disorders. Eating disorders may increasingly be viewed not only as psychiatric conditions but environmentally induced or exacerbated disorders linked to platform design.

Clinicians should begin to document social media exposure patterns and incorporate platform use into diagnostic frameworks. This could strengthen litigation evidence and insurance coverage arguments.

In addition, eating disorders may be reframed as partially technology-mediated disorders. This parallels lung cancer (tobacco) and opioid addiction (pharmaceutical design and distribution).

The Meta and Google verdicts do not merely increase litigation risk, they signal a paradigm shift in how harm from digital systems is understood and adjudicated. For eating disorders, the implications are profound:

A viable legal theory now exists
Causation barriers are weakening
Platform design is becoming justiciable
Large-scale settlement frameworks are increasingly likely

Most importantly, these developments may redefine eating disorders not only as clinical phenomena, but as foreseeable outcomes of engineered environments optimized for engagement at the expense of psychological safety.

If this trajectory holds, the next phase of litigation will not ask whether platforms contributed to eating disorders, but to what extent, and at what cost.

Category Laundering and Manipulation.

At ICED 2026, Dr. Rebecca Peebles participated in the panel discussion, “From Recognition to Action: Addressing Weight Stigma in Family-Based Treatment.” Apparently, during her part of the presentation, Dr. Peebles utilized this slide:

Dr. Cheri Levinson provided additional information about this slide when she posted on social media, “People with a BMI of 25-37 actually have the LOWEST mortality rates. Oh what?! Being fat is actually “healthy.”

This is where credibility disappears and the argument goes from substance to hyperbole.

It is widely accepted that BMI is not the best indicator of health. But, the conference slide did not merely criticize BMI. That would be easy enough to defend. BMI is crude. BMI is less useful at the individual level for people who are unusually short, tall, muscular, older, or racially and ethnically unlike the populations from which many cutoffs were derived. In 2023, the AMA said that BMI should not be used alone and should be considered with other measures, including visceral fat, body composition, waist circumference, and genetic or metabolic factors.

But that is not the same claim as saying that people with a BMI from 25 to 37 have the lowest mortality. That claim does something different. It takes a legitimate criticism of BMI and uses it to smuggle in a materially broader proposition that the evidence does not support.

The CDC’s recognized adult BMI categories are straightforward:

healthy weight, 18.5 to less than 25;

overweight, 25 to less than 30;

class 1 obesity, 30 to less than 35;

class 2 obesity, 35 to less than 40;

class 3 obesity, 40 or higher.

A BMI range of 25–37 is a rhetorically constructed category, not a medically coherent one. It fuses the categories, “overweight,” all of class 1 obesity, and the lower half of class 2 obesity, then stops before the evidence becomes harder to spin.

That is why the numbers are misleading. It is not a neutral scientific category. It is an advocacy category.

Flegal et al. 2013 did find that the standard overweight category, BMI 25 to less than 30, had lower all-cause mortality than the normal BMI reference group, with a summary hazard ratio of 0.94. But the same paper found that obesity overall, BMI 30 and above, had higher mortality, with a hazard ratio of 1.18, and that BMI 35 and above had an even higher hazard ratio of 1.29. So Flegal cannot honestly be used to say that 25 to 37 is the lowest mortality range.

The more recent U.S. NHIS analysis is also narrower than the slide’s implication. That study, using 1999 to 2018 NHIS data linked to the National Death Index, found adjusted hazard ratios of 0.95 for BMI 25.0 to 27.4 and 0.93 for BMI 27.5 to 29.9 compared with BMI 22.5 to 24.9. But the same article concluded that mortality risk was elevated by 21% to 108% among participants with BMI 30 or greater, while noting important age differences.

That is the evidentiary problem. The slide and argument appear to rely on the most favorable interpretation of the overweight literature, then extends it into obesity ranges where the supporting evidence weakens and reverses.

Unquestionably, the rhetorical sequence is efficient. First, attack BMI as imperfect. Second, invoke the 1998 cutoff change to make BMI categories look arbitrary. Third, cite Flegal for the proposition that “overweight” people had lower mortality. Fourth, visually expand the favorable zone on a graph until it appears to cover a much wider range. The audience receives one simplified message: higher weight is not associated with worse health and conventional BMI categories are suspect.

But each step requires a correction.

The 1998 NIH/NHLBI guideline did classify BMI 25 to 29.9 as overweight and BMI 30 or greater as obese, and it treated adults with BMI 25 or greater as at risk for associated morbidities including hypertension, high cholesterol, type 2 diabetes, and coronary heart disease. Before that transition, U.S. reporting had used higher sex-specific overweight thresholds, including BMI 27.8 for men and 27.3 for women. That history may show that BMI categories are policy judgments layered on epidemiology. It does not prove that BMI 37 is part of a lowest mortality range.

Further, the Flegal study is a mortality study, not a comprehensive health study. It examined all-cause mortality, not diabetes incidence, cardiovascular disease, sleep apnea, mobility limitation, fertility complications, liver disease, medication burden, surgical risk, or quality of life. Mortality is a blunt endpoint. A person can be alive and still have those health issues. Converting “not dead during the study window” into “healthy” is not epidemiology. It is overreach.

Nor does “BMI is imperfect” mean “BMI is useless.” The CDC says BMI is a screening measure that should be considered with other factors when assessing health. The AMA took essentially the same position: BMI has limits, but it can be helpful in certain scenarios when its benefits and limits are understood.

That is the honest conclusion. BMI alone is inadequate. But a nonstandard 25 to 37 range is worse. BMI is at least a disclosed measurement. 25 to 37 is a constructed talking point. A serious health assessment does not replace BMI with ideology. It replaces BMI alone with clinically meaningful data.

The eating disorder community deserves facts, evidence, scientific and medically based knowledge. Not empty rhetoric and not manipulated numbers to support a false narrative.

Families suffering from eating disorders deserve the unvarnished truth. Those families, those who live with, suffer from and sometimes, have to endure the unthinkable are why this community exists.

Manipulation of research and statistics to support a false narrative should not be tolerated. The community deserves better. Families deserve better.

Recently, one of the creators of the Inclusive Eating Disorder Certification Program questioned how I can speak so vehemently about collaboration when I am, in that person’s view, so divisive in the eating disorder community.

That question deserves an answer because it exposes one of the field’s most persistent evasions. Many people in the eating disorder community use the word collaboration when they mean agreement, access, approval, politeness, ideological alignment, or silence. They do not mean objective testing of claims nor public disagreement nor bringing clinicians, researchers, families, former patients, regulators, and grieving parents into the same room and forcing uncomfortable facts into view.

They mean … stop making people uncomfortable.

That is not collaboration. That is compliance. It is performative. And I reject that premise.

Collaboration does not require making peace with dysfunction. Nor does it require vacuous flattering of certification programs, credential vendors, professional organizations, treatment platforms, social media advocates, or ideological factions that have all failed to produce measurable accountability in a field where our loved ones continue to die. Collaboration does not require pretending that every certificate confers expertise, every advocate with a platform has wisdom, or every institution fluent in inclusion is clinically serious.

Serious collaboration begins with reality. And reality is divisive only to those protected by illusion.

The eating disorder field has a long history of confusing tone with integrity. Raise direct questions about mortality, treatment failure, private equity, unregulated coaching, credential inflation, ideological capture, weak standards, or professional self-protection, and parts of the field suddenly discover false civility. The same people who tolerate fragmentation, silence, opaque outcomes, and avoidable harm become deeply concerned about whether the person naming the problem is pleasant enough.

That is insufferable and should not be tolerated.

Our loved ones continue to die. The body count escalates. Families are being misled. Patients are cycling through levels of care without durable recovery. Parents are paying enormous sums of money for treatment they cannot evaluate. Clinicians are practicing inside reimbursement systems that often dictate care more aggressively than science does. Militant activists are attempting to bastardize the DSM-V to fit their short-sighted understanding of eating disorders. Treatment companies market hope while withholding the outcomes data that would allow the public to judge whether that hope is justified. Certificates multiply while families struggle to distinguish education from regulation, training from authority, and branding from protection.

If exposing those realities constitutes being divisive, then the division was already there. I did not create it. I just refuse to decorate it or surrender to it.

Without common goals and objectives, there can be no collaboration. Diametrically different goals are the death of collaboration.

Collaboration is not indiscriminate. People cannot collaborate through evasion. People cannot treat bad evidence as merely another perspective. A community is not required to accept a biased certificate as a substitute for licensure, medical competence, supervision, public discipline, or enforceable patient protection. A community should not become a chorus of reassurance while mortality remains the quietest fact in the room.

The accusation that I am divisive says more about the accuser’s definition of community than it says about my commitment to collaboration. For that matter, what is this community I am allegedly dividing?

The patients? The families? Serious clinicians? Researchers? I have stood with and helped each of those groups.

The certification sector? If so, let me be precise. Certification is not regulation. A certificate may mean someone merely completed a course. It does not mean a state has granted legal authority to treat vulnerable people. It does not mean a public disciplinary body exists. It does not mean families have meaningful protection if harm occurs. In a field where the public already struggles to distinguish therapist, dietitian, physician, coach, advocate, consultant, mentor, educator, and influencer, credential inflation is not harmless. It can become structural erosion sold as progress.

The question is not whether a certification program uses the language of inclusion. The question is whether it improves clinical seriousness, patient protection, measurable outcomes, and public accountability. The question is, will it decrease the crippling mortality rate haunting eating disorders. Those questions must be asked directly.

I do not oppose inclusion. To the contrary. Access to care is an incredibly important issue which must be addressed intelligently. What I do oppose is using inclusion as a shield against scrutiny to perpetuate a close minded or radical political or social justice agenda. I will not gladly suffer anyone who attempts to use the illness that took my daughter’s life as a platform to spew forth their radical political or social justice views. That I will not forgive. Nor allow.

There is a difference between being divisive and drawing necessary lines. A field that cannot distinguish between those things is not mature enough to police itself.

That is exactly where collaboration is needed. But collaboration cannot begin with a conclusion dictated by activist commitments.

The accusation of divisiveness is efficient because it avoids the merits. It also does not answer whether the criticism is true. It does not address whether standards are weak, outcomes are hidden, research is underfunded, coaching is dangerous when it crosses into treatment, certificates confuse the public, or ideology has displaced scientific seriousness in parts of the field.

The eating disorder field does not need fewer divisions if the price of unity is silence. It needs better divisions. It needs a division between evidence and performative conduct. Between licensure and certificate marketing. Between peer support and unsupervised treatment. Between inclusion and ideological capture. Between compassion and institutional self-protection. Between families asking questions and professionals resenting those questions. Between people trying to save lives and people trying to preserve their place and social platform in the room.

A serious community does not fear those divisions. It clarifies them. It embraces them.

I am in this dysfunctional field because my daughter died. That is not a credential. It is not a claim to infallibility. It does not make every judgment correct. It does, however, make one thing impossible: I cannot pretend the stakes are lower than they are so that professionals, advocates, certification creators, treatment executives, or institutional insiders feel more comfortable. Once you are cast into a room no parent should enter and from which they cannot escape, you do not owe deference to people who think public accountability is a breach of etiquette.

So let the record be clear.

I strongly believe in collaboration. But I will not collaborate with cowardice. I will not collaborate with incompetence nor with people who use the language of harm to avoid hard questions. I will not collaborate with credentialing efforts that blur the line between education and public protection. I will not collaborate with those who mistake ideological fluency for clinical depth. I will not collaborate with institutions that protect reputation more aggressively than patients. I will not collaborate with people who believe the worst thing one can do in this field is to be disruptive.

The worst thing one can do in this field is normalize failure.

I will collaborate with anyone serious enough to put patients, families, evidence, mortality, and accountability above personal brand, institutional comfort, political fashion, professional status or profiteering. But I will not confuse collaboration with surrender. I will not soften the truth so the field can continue mistaking civility for progress. Perhaps the community should adopt similar beliefs.

If that makes me divisive, then so be it and I wear that label proudly. Because that type of division is necessary. And long overdue.

The Eating Disorder Community is in Decline and I will not Pretend Otherwise

I am angry.

Not performatively angry. Not professionally offended. Not angry because I lost an argument on the internet or failed to receive applause from a community that mistakes approval for moral authority.

I am angry because my daughter is dead.

Morgan died from anorexia. On October 30, 2016, a brilliant light was extinguished. That date is not rhetoric. It is not branding. It is not “a platform,” as some room temperature IQ marketer once had the gall to call this advocacy.

It is the dividing line in my life. Before it, I was a father. After it, I became something else … a grieving father forced into a world that talks endlessly about compassion while tolerating cowardice, corruption, incompetence, ideological vanity and institutional decay.

The eating disorder community does not like anger like mine because it cannot domesticate it. It cannot convert it into a panel discussion, a diversity statement, a certification module or a social media campaign. It cannot make it polite enough to ignore.

That is why it wants people like me to be quiet.

And yet, I will not be quiet. I cannot be quiet.

After my daughter died, I tried to serve. That is what grieving parents often do when the alternative is collapse. You try to turn pain into usefulness. You tell yourself that if you can help one family, warn one clinician, reach one school, educate one employer or reach one terrified parent, then maybe the unbearable can be forced into some form of meaning.

I gave TEDx talks. I worked with physicians. I organized presentations for Apple and Raytheon. I spoke to school counselors, nurses, churches, treatment programs, television stations and radio audiences. I hosted mental health programming. I tried to bring serious voices into public spaces where eating disorders were still misunderstood, minimized or sentimentalized.

And still, it was not enough.

Eventually I learned far too late what many families have not yet learned. The eating disorder community is not merely underfunded or misunderstood. It is dysfunctional, fragmented and frightened of accountability. It too often rewards performance over substance, ideology over science, credentials over courage and consensus over truth. Worst of all, it has become increasingly comfortable using death as scenery while fighting over status.

The public is told this is a community of care. Families are told to trust the experts, the advocates, the organizations, the conferences, the language and the credentials. But behind the soft vocabulary sits a harder truth. This field remains divided on treatment, weak on accountability, vulnerable to private equity extraction, susceptible to ideological capture and far too willing to treat bereaved families as inconvenient when they ask direct questions.

The result is moral rot with professional polish.

The certification sector epitomizes this reality. Credentials now multiply like weeds. Every faction seems to have a course, a module, a preferred vocabulary and a moral test. Some programs lean clinical. Others appear more interested in political catechism than medical seriousness. One can now encounter training materials that seem more committed to ideological confession than saving lives.

Meanwhile, families still cannot get clear answers to basic questions. What treatment works best for which patient, at what stage, under what conditions and with what measurable outcome? What standards are truly evidence based? Who is tracking deaths? Who is tracking failed discharges? Who is tracking relapse after residential treatment? Who is accountable when a facility markets hope, collects enormous fees and sends a patient home no safer than when she arrived?

The field has conferences, hashtags, consultants, committees, coalitions and continuing education products. It also has frauds and charlatans.

What it does not have is a unified standard of excellence worthy of the dead.

That is the indictment.

When insurance companies dictate care, the community complains. When private equity turns residential treatment into a revenue model, the community whispers. When families are bankrupted, the community sympathizes. When clinicians disagree on basic treatment principles, the community schedules another panel. When misinformation spreads, the community looks the other way if the messenger belongs to the right social tribe. When organizations drift from mission into self-protection, the community ignores it.

But, when a grieving father says the system is failing, some of these same people suddenly pretend to discover standards of civility.

No.

Civility is not the highest virtue in a field where people are dying. Truth is. Accountability is. Competence is. Scientific seriousness is.

The eating disorder community has too often chosen theater. It has chosen language games. It has chosen familiar alliances over public correction. It has chosen to protect reputations more aggressively than families.

I have seen organizations that once claimed noble missions become captive to vanity, ideology or institutional self-interest. I have seen advocates confuse unresolved pain with public wisdom. I have seen professionals hide behind credentials while refusing to confront obvious dysfunction. I have seen activists reduce complex, lethal brain-based illnesses to social talking points. I have seen people who should know better treat mortality as an inconvenience to their preferred narrative.

This is not progress. It is decline.

And yes, I have made my fair share of mistakes. Grief does not make a man infallible. Pain does not make every judgment wise. I have spoken too sharply at times. I have misread people. I have trusted the wrong people. I have reacted when restraint would have served better.

But my mistakes are my own. They do not absolve the community of its failures.

That dodge has been used too often. Attack the messenger. Question his tone. Whisper about his anger. Pretend that if the grieving father is imperfect, then the institution is clean.

It is not.

NEDA did not need to become a stage for ideological conflict. IAEDP did not need outside pressure before obvious issues were confronted. Board certification did not need to become needlessly expensive or exclusionary. Treatment programs did not need to operate inside opaque business structures while families were told to trust the brand. The phrase “terminal anorexia” did not need to enter the field with the casual horror of professional abstraction while families wondered whether the system was preparing to give up on the very patients it had failed to save.

Again and again, the pattern is the same. The community avoids hard accountability until someone forces the issue. Then, after reform becomes unavoidable, the same community pretends the disruption was the problem.

It was not.

The problem was the misconduct. The problem was the silence. The problem was the cowardice before the lawsuits, complaints, public records and exposure.

When I acted, reform followed. Taxes, penalties and interest had to be addressed. Certification reforms moved. Chapters gained independence. Costs were reduced. Therapists were spared unnecessary expense. Research benefited. Conversations shifted. People who had been privately afraid, began to speak. I connected parents with doctors. And visited their loved ones in treatment centers.

Very few said thank you.

That is fine. I did not bury my daughter in exchange for applause.

But I will not accept lectures from people who confuse politeness with integrity. Nor will I accept moral instruction from those who watched dysfunction metastasize and called their silence professionalism.

The eating disorder community needs far less performance and far more courage. It needs fewer ideological purity tests and more scientific humility. Fewer certification pseudo empires and more measurable outcomes. Fewer self-appointed gatekeepers and more public accountability. Fewer slogans and more data. Fewer branded advocates and more grieving families at the center of the record.

It also needs to stop pretending that anger is the enemy.

Anger is not the enemy when children die, families are misled, treatment becomes a business model, public messaging drifts from science and organizations protect themselves before they protect patients.

I am angry because the stakes are life and death. I am angry because this field should be better than it is. I am angry because the public still does not understand eating disorders with the urgency they deserve. I am angry because families still enter this system terrified, uninformed, financially exposed and dependent on people who may or may not be worthy of that trust.

The enemy is complacency. The enemy is cowardice. The enemy is institutional vanity. The enemy is the professional instinct to survive scrutiny rather than deserve trust.

One more parent will soon stand where I stand. One more parent will replay the last conversation. One more parent will wonder what they missed. One more parent will be told it was not their fault and still wake each morning inside a private prison where no acquittal holds. One more parent will discover that grief is not a season. It is a climate.

So no, I will not soften this. I will not stand down. To the contrary. It is long past time for escalation. That is because the eating disorder community is in a continuing decline. And that decline is measured in more lives being taken.

A serious community welcomes scrutiny. A serious community puts mortality first. A serious community builds a public, adversarial, evidence driven forum where the brightest clinicians, researchers, families and survivors debate standards of care in full view. A serious community demands transparent outcomes from treatment providers. A serious community tracks deaths, relapses, readmissions, restraints, failed discharges, insurance denials, financial exploitation and conflicts of interest. A serious community would stop hiding behind compassion while avoiding accountability.

The eating disorder community is not serious.

That can and must change. But it will not change through another slogan, conference theme, awareness week, land use acknowledgment, moral lecture, branded certification or circular panel discussion where everyone already agrees before the microphones are turned on.

It will change when people with something to lose tell the truth. It will change when families stop mistaking credentials for character. It will change when organizations understand that their missions are not ornaments. It will change when clinicians accept that disagreement is not violence and scrutiny is not persecution. It will change when advocates stop using eating disorders as vehicles for every fashionable political obsession and return to the central fact that these illnesses kill.

My daughter died. That is where this begins. And that is where every excuse ends.

I do not write from theory. I write from the room no parent should enter. I write from the silence after the funeral. I write from the years in which grief becomes ordinary and yet still remains unbearable. I write from the knowledge that no award, no speech, no lawsuit, no reform, no public victory and no act of service can restore the life that was taken.

And so, I write. The eating disorder community can continue to resent my anger if it wants. But, I have earned my seat. I have earned it through the most horrific way imaginable. My seat in this dysfunctional community was paid with the dearest blood possible.

And until this community chooses truth over theater, science over slogans, accountability over self-protection and patients over politics, I will keep speaking and fighting.

Not because I enjoy the fight.

Because my daughter is dead.

And too many people who claim to care have become far too comfortable living with that kind of loss … so long as it belongs to someone else.

WHAT’S IN YOUR WALLET?

The last chapter in Center for Discovery’s all but played out existence is being written.

The May 11 auction of its parent company, Discovery Behavioral Health was not an ordinary sale process but instead, was a forced unwinding of a leveraged behavioral health platform. Public reporting indicates that Discovery’s lenders, Capital One and HPS Investment Partners, had already taken control after declaring the company in default on roughly $270 million in debt, removing the board and installing their own leadership structure. The auction, led by Paul Weiss lawyers, offered Discovery’s behavioral health portfolio, including eating disorder, substance use, and psychiatric assets, on an “as-is, where-is” basis to address nearly $270 million in outstanding debt.

As of now, there has been no public confirmation of the winning bidder, sale price, asset allocation or whether any third-party buyer emerged. But the structure of the process points toward the most likely result. A lender-controlled outcome, with Capital One, acting with HPS, positioned to prevail through a credit bid or credit bid equivalent rather than a cash purchase by an outside buyer.

That result would not be surprising. Under the UCC Article 9, after default a secured party may dispose of collateral in a commercially reasonable sale, including as a unit or in parcels, and a secured party may purchase the collateral at a public disposition. For a third-party bidder, Discovery’s assets present obvious friction. The portfolio was reportedly offered all or nothing and as is, where is. That means any outside bidder would need to underwrite not only the attractive assets, but also the weaker facilities, legacy liabilities, lease exposure, operational instability, payer issues and regulatory complexity embedded across the company. A secured lender by contrast, can bid its debt, take control and then attempt to sell the pieces separately.

For Center for Discovery, the immediate implication is probably not an immediate, sudden shutdown. Treatment businesses lose value quickly when census collapses, clinicians leave, licenses are disrupted or referral sources lose confidence. Discovery still publicly markets a national behavioral health platform with residential, partial hospitalization, intensive outpatient and online services. Center for Discovery itself continues to present eating disorder treatment across residential, PHP, and IOP levels of care. A lender trying to maximize recovery has an incentive to preserve going-concern value long enough to market the viable pieces.

But continuity is not the same as stability.

The more likely path is a breakup. Center for Discovery is likely to be separated from less attractive parts of the Discovery Behavioral Health portfolio and marketed as a distinct eating disorder treatment asset. That would make financial sense. Eating disorder treatment has brand value, payer relationships, geographic reach and a continuum of care that can be sold to a strategic buyer or private equity-backed behavioral health platform. Yet that same logic creates risk. Once Center for Discovery becomes an asset to be monetized rather than a clinical platform to be rebuilt, the incentives may shift toward margin protection, census preservation and sale readiness.

The greatest concern is the likely emphasis on PHP and IOP. These levels of care are increasingly attractive to investors because they carry a lower cost structure than residential treatment. They require less real estate intensity, less overnight staffing, fewer facility burdens and can be scaled more easily across markets. Industry reporting has also noted that payers favor outpatient settings such as PHP and IOP over residential programs because of lower cost and comparable outcome claims. Behavioral Health Business has likewise reported that PHP and IOP programs have expanded because they fill the gap between outpatient therapy and inpatient or residential care, while appealing to payers seeking to avoid more expensive inpatient stays.

That financial logic is precisely why the clinical risk is serious. Eating disorder care is not interchangeable across levels of care. Center for Discovery describes residential treatment as 24/7 structured support, PHP as full-day treatment often used as a step-down from residential care and IOP as a lower-intensity program for patients able to function with fewer treatment hours. If the next owner, or interim lender-controlled management group, treats PHP and IOP primarily as higher-margin substitutes for residential care, patients could be pushed into levels of care that are financially efficient but clinically insufficient.

The danger is not merely theoretical. A distressed sale process creates pressure to make the asset look cleaner, leaner and more profitable. That can mean cutting underperforming residential beds, consolidating programs, reducing staffing intensity, accelerating step-downs and emphasizing outpatient census. Each move may be defensible in isolation. Together, they can alter the clinical character of the program.

For families and clinicians, the question after the auction is therefore not only who owns Center for Discovery. The harder question is what the new owner intends to preserve. A responsible transition would protect clinical staffing, maintain appropriate level-of-care determinations, honor existing treatment plans, preserve continuity for patients already admitted and avoid using PHP or IOP as a financial substitute for residential treatment when residential care is clinically indicated.

The likely auction result may give Capital One and HPS a path to recover part of their debt. It does not answer the more important question for patients … whether Center for Discovery will remain a treatment system or become a collection of monetizable outpatient assets.

Perhaps Capital One’s catch phrase, “What’s in your wallet?” needs to be adjusted to “What’s in your wallet? Less, if Capital One holds the note.”

The latest hobgoblin to perplex the eating disorder community is the use of GLP-1 medications. Competing presentations and articles are being published. Accusations of bias are already bandied about. This raises the inevitable question … was the talk or article biased or was it simply incomplete?

That distinction matters more than it may first appear. To call a presentation “biased” is to suggest a fundamental defect. It implies bad faith, intellectual contamination, or a failure so basic that the speaker’s credibility is diminished. The word often operates as an accusation, and once it enters the lexicon, the conversation itself changes. People retreat into defensive positions. Groups harden. The possibility of productive engagement narrows.

But to refer to a presentation as “incomplete” is different. “Incomplete” does not excuse weakness. It identifies it with precision. It says the subject required more voices, more context, more rigor, more disciplines, more lived experience, more challenge. It leaves room for the possibility that the presenter was building something rather than distorting something. It invites participation rather than condemnation. It allows the field to ask; What is missing? Who was not included? What assumptions were left untested? What would make this stronger?

That distinction, bias versus incompleteness, goes to the heart of a systemic problem within the eating disorder community.

Too often the field does not possess the structures necessary to metabolize disagreement. It does not consistently bring opposing views into disciplined, accountable deliberation. Instead, it allows major questions to emerge through fragmented presentations, isolated publications, advocacy statements, rebuttals, counter-rebuttals, and public controversy. The result is not consensus. It is not clarity. It is not reform. It is serial reaction and in some cases, overreaction.

Terminal anorexia, weight stigma, obesity, residential treatment, involuntary care, medical stabilization, private equity, insurance denial and the role of families. The debate over GLP-1 medications is only the latest example.

Given the stakes, the introduction of GLP-1s into the eating disorder conversation should have triggered a process proportionate to the seriousness. These medications raise profound clinical, ethical, metabolic, psychological, social and even spiritual questions. They implicate body weight, appetite, medical risk, obesity treatment, relapse vulnerability, access to care, stigma, autonomy, coercion, and the meaning of recovery itself.

A mature field would have responded by convening a serious, multidisciplinary process. Not a panel designed to affirm one position. Not a paper written from one perspective. Not a series of advocacy reactions after the fact. A real process.

That process should have included eating disorder clinicians, obesity medicine specialists, psychiatrists, endocrinologists, researchers, ethicists, patients, families, disability-rights advocates, theologians, legal scholars, and people with lived experience across different diagnostic and body size realities. It should have directly examined assumptions. It should have asked what is known, what is unknown, what is being inferred, and what risks are being underestimated. It should have distinguished clinical concern from ideological reflex. It should have clarified where caution is warranted and where fear may be substituting for evidence.

Instead, the field did what it too often does. It processed the issue through fragmentation.

One group speaks. Another group objects. A paper appears. A blog responds. A statement circulates. A conference panel frames the issue one way. A counter-panel frames it another. Advocates describe harm. Clinicians defend nuance. Researchers ask for data. Patients feel unseen. Families remain confused. Positions harden before the field has created a shared table at which those positions can be tested.

And nothing durable is built. This is not structured deliberation. It is intellectual trench warfare. This trench warfare has become the eating disorder field’s primary method of adjudication.

What does not emerge is institutional architecture capable of absorbing disagreement and converting it into accountable consensus. That absence is not a minor procedural flaw. It is one of the field’s central weaknesses.

A field dealing with a life-threatening illness cannot rely on sequential publication as its primary conflict resolution mechanism. Publication has value. Scholarship matters. Commentary matters. Advocacy matters. But none of those alone can substitute for a legitimate consensus building structure. Papers do not cross-examine assumptions in real time. Advocacy statements do not reconcile competing clinical realities. Conference talks do not create binding standards. Public rebuttals do not necessarily produce shared definitions.

They often produce only more hardened factions.

A system that can only process new and consequential concepts through this fragmented process is not demonstrating intellectual vitality. It is demonstrating procedural weakness. It is showing that it lacks the mechanisms needed to test its most important ideas before they migrate into practice, policy, treatment settings, insurance decisions and public discourse.

That matters because ideas in this field are not abstract. They become clinical posture. They influence whether patients are hospitalized or discharged. They shape how risk is understood. They affect whether families are included or marginalized. They determine whether weight loss is celebrated, feared, treated, or ignored. They define whether a patient is viewed as resistant, autonomous, hopeless, harmed, empowered, or in need of urgent intervention.

Language becomes practice. Practice becomes outcome. Outcome becomes life or death.

The eating disorder community cannot continue treating disagreement as contamination. It cannot keep mistaking opposition for hostility. It cannot continue allowing each faction to speak from its own platform while pretending that the existence of multiple platforms equals meaningful discourse. It does not.

Real discourse requires structure. It requires shared rules. It requires the willingness to sit beside a person who sees the issue differently and remain engaged long enough to understand why. It requires humility from researchers, clinicians, advocates, families, and patients alike. It requires the recognition that no single constituency owns the truth. Separate truths may coexist. A serious field must be able to hold both simultaneously.

The current model does not do that well. The current model rewards position taking more than integration. It rewards rapid response more than disciplined synthesis. It rewards moral clarity, even when the underlying issue is clinically and ethically complex. It allows organizations to issue statements, scholars to publish frameworks, advocates to mobilize outrage, and clinicians to continue practicing amid uncertainty … without requiring the field as a whole to reconcile competing truths.

That is not consensus. That is convenience.

The path forward is not silence. It is not politeness for its own sake. It is not pretending that all views are equally supported by evidence. Some arguments are stronger than others. Some claims are dangerous. Some assumptions deserve to be challenged directly. But the challenge must be structured.

The field needs a new model for consequential disagreement. When the next major issue arises the response should not be another isolated paper followed by predictable backlash. It should be a convened process with opposing experts, clear questions, transparent assumptions, defined evidentiary standards, patient and family participation, ethical review, and a published consensus document that identifies agreement, disagreement, uncertainty, and practical guidance.

Not every issue will end in unanimity. It should not. Forced consensus can be as dangerous as fragmentation. But a credible process can at least clarify the boundaries of disagreement. It can say … here is what we know; here is what we do not know; here is where clinical caution is justified; here is where ideology may be exceeding evidence; here is where patient safety requires action; here is where further research is essential; here is how families and clinicians should proceed in the meantime.

That would be progress.

The eating disorder field does not suffer from a lack of passion. It suffers from a lack of integrative structure. It has brilliant clinicians, committed researchers, courageous patients, grieving families, thoughtful advocates, and people of genuine moral seriousness. But intelligence distributed across factions does not automatically become wisdom. Wisdom requires architecture.

The eating disorder community must move beyond the zero-sum game. It must stop treating incompleteness as bias and disagreement as betrayal. It must build the institutional capacity to hold complexity without collapsing into camps. It must recognize that the goal is not for one tribe to defeat another. The goal is to produce better care, better standards, better evidence, better ethics, and better outcomes.

Lives depend on whether the field can learn to do that.

A DAD'S JOURNEY WITH EATING DISORDERS

Musings on Mental Health and the Eating Disorder Industry

Menu

Equip’s Transition

Five Million Dollars is not a Victory. It is an Indictment.

Category Laundering and Manipulation.

The Eating Disorder Community is in Decline and I will not Pretend Otherwise

WHAT’S IN YOUR WALLET?

Menu

Share this:

Share this:

Share this:

Share this:

Share this:

Share this:

Share this:

Share this:

Share this:

Share this: